Molnupiravir represents a promising development in the effort against COVID-19, functioning as an administered antiviral agent. Initially designed to combat the flu, its unique mechanism of action – introducing errors into the virus's genetic code – has demonstrated success in reducing the risk of severe illness and hospitalization in high-risk